ANI Pharmaceuticals reported $81.77M in Selling and Administration Expenses for its fiscal quarter ending in June of 2025.


Selling And Administration Expenses Change Date
AbbVie USD 3.25B 40M Jun/2025
ANI Pharmaceuticals USD 81.77M 5.24M Jun/2025
Aurora Cannabis CAD 45.63M 7.45M Jun/2025
Canopy Growth CAD 40.12M 504K Jun/2025
Eli Lilly USD 2.75B 390.8M Jun/2025
Hikma Pharmaceutical USD 288M 8M Dec/2024
Knight Therapeutics CAD 25.48M 119K Sep/2024
Novartis USD 3.44B 60M Jun/2025
Perrigo USD 273.1M 8.1M Jun/2025
Sun Pharmaceuticals INR 24.89B 637.6M Mar/2025
Teva Pharmaceutical Industries USD 959M 40M Jun/2025